Prespecified pooled analysis of two RCTs (2682 participants with COPD and frequent exacerbations): astegolimab reduced moderate/severe exacerbation rate vs placebo by 15% every 2 weeks (RR 0.85) and 12% every 4 weeks (RR 0.88), and was well tolerated.
Secondary analysisn = 2,682
Wedzicha et al. Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials